Biostem Technologies OTC Stock Executives
| BSEM Stock | USD 14.44 0.98 6.36% |
Biostem Technologies employs about 13 people. The company is managed by 6 executives with a total tenure of roughly 8 years, averaging almost 1.0 years of service per executive, having 2.17 employees per reported executive. Analysis of Biostem Technologies' management performance can provide insight into the firm performance.
| Jason Matuszewski Chairman Chairman and President and Secretary |
Biostem |
Biostem Technologies Management Team Effectiveness
The company has return on total asset (ROA) of (0.6018) % which means that it has lost $0.6018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2102) %, meaning that it created substantial loss on money invested by shareholders. Biostem Technologies' management efficiency ratios could be used to measure how well Biostem Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Biostem Technologies Workforce Comparison
Biostem Technologies is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 1,082. Biostem Technologies claims roughly 13.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.
Biostem Technologies Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Biostem Technologies Price Series Summation is a cross summation of Biostem Technologies price series and its benchmark/peer.
Biostem Technologies Notable Stakeholders
A Biostem Technologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biostem Technologies often face trade-offs trying to please all of them. Biostem Technologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biostem Technologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jason Matuszewski | Chairman and President and Secretary | Profile | |
| Andrew VanVurst | COO Director | Profile | |
| Irmgard MD | International Officer | Profile | |
| Larry Jones | Chief Officer | Profile | |
| Michael CPA | Chief Officer | Profile | |
| David Woynarowski | Chief Officer | Profile |
About Biostem Technologies Management Performance
The success or failure of an entity such as Biostem Technologies often depends on how effective the management is. Biostem Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biostem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biostem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Biostem Technologies is traded on OTC Exchange in the United States.
The data published in Biostem Technologies' official financial statements typically reflect Biostem Technologies' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Biostem Technologies' quantitative information. For example, before you start analyzing numbers published by Biostem accountants, it's essential to understand Biostem Technologies' liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Biostem Technologies Workforce Analysis
Traditionally, organizations such as Biostem Technologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biostem Technologies within its industry.Biostem Technologies Manpower Efficiency
Return on Biostem Technologies Manpower
| Revenue Per Employee | 194K | |
| Revenue Per Executive | 420.3K | |
| Net Loss Per Employee | 183.8K | |
| Net Loss Per Executive | 398.2K |
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.